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Abstract: Environmental exposures and genetic susceptibility can contribute to lung function 
decline in chronic obstructive pulmonary disease (COPD). The environmental factors are better 
known than the genetic factors. One of the commonest reasons of accelerated forced expiratory 
volume in one second (FEV1) decline in COPD is the continuation of the smoking habit. In 
addition, COPD patients have frequent acute respiratory infections which can also accelerate 
the decline of FEV1. All of the gene variants that have been reported in association with accel-
erated decline of lung function in COPD represent advancement because the ﬁ  ndings generate 
plausible hypotheses about the possible mechanisms by which gene products could accelerate 
or avert FEV1 decline. Unfortunately, the results have not been consistently replicated and, 
animal models required to functionally assess the genetic ﬁ  ndings, have not yet yielded suf-
ﬁ  cient data. Genome-wide association studies should provide more deﬁ  nitive results in COPD 
and other multigenic conditions. Until these studies are reported, the data to date suggest that 
products encoded by the alpha-1 antitrypsin, some matrix metalloproteinases, and a number of 
antioxidant genes are associated with accelerated FEV1 decline in COPD. Data on gene variants 
associated with acute exacerbations of COPD are now emerging.
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The Lung Health Study enrolled 5887 participants with mild-to-moderate chronic ob-
structive pulmonary disease (COPD) in a 5-year study to evaluate the effects of smoking 
cessation and maintenance therapy with inhaled ipratropium on the annual change in 
lung function (Anthonisen et al 1994). Large reductions in smoking amount (of up to 
50%) had no observable effect on the decline in forced expiratory volume in one second 
(FEV1). Instead, participants in the Lung Health Study who quit smoking and remained 
abstinent (sustained quitters) exhibited a signiﬁ  cant increase in FEV1 during the 1st year 
after smoking cessation, followed by a steady decline comparable with that reported for 
never-smokers (Anthonisen et al 2002). Among smokers who achieved intermittent peri-
ods of complete smoking abstinence but at other times maintained their regular smoking 
habit (intermittent quitters), the annual rate of decline in FEV1 was intermediate between 
that of sustained quitters and continuing smokers who did not have periods of abstinence. 
Healthcare providers should continue to emphasize that complete smoking cessation is 
the best approach to obtain a beneﬁ  cial effect in pulmonary function (Simmons et al 
2005). In addition, prevention of acute exacerbations of COPD (AECOPD)—through 
appropriate vaccinations (Bateman et al 2004) and combined treatment with long-acting 
bronchodilators (LABA) and inhaled corticosteroids (ICS) (Soriano et al 2003; Szaf-
ranski et al 2003)—is also important as AECOPD can provoke steeper decline of FEV1 
over time, albeit such decline is less pronounced in sustained quitters than in smokers 
(Kanner et al 2001; Wilkinson et al 2003).
The mechanisms through which cigarette smoking and AECOPD accelerate FEV1 
deterioration are complex, but a predominant mechanism is the increased oxidative International Journal of COPD 2007:2(2)  118
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stress in the airways (Nagai et al 2006; Rytila et al 2006; Yigla 
et al 2006). Oxidative stress induces transcription in a number 
of antioxidant genes such as the glutathione S-transferase 
(GST) (ie, GSTM1, GSTT1, and GSTP1), heme oxygenase 
(HMOX)-1, and microsomal epoxide hydrolase (mEPHX). 
Yet in some subjects, these genes present polymorphisms 
that are associated to accelerated decline of lung function. A 
gene promoter polymorphism (characterized by >33 repeats) 
in HMOX-1 is associated with steeper mean FEV1 decline 
(62 ml/year) in heavy smokers (Guenegou et al 2006) in 
accordance with previously reported ﬁ  ndings (Yamada et al 
2000). An association between rapid decline of mean FEV1 
(approximately 150 ml/year) and the presence of all three 
GST polymorphisms (GSTM1, GSTT1, and GSTP1) in 
smokers from the Lung Health Study has also been described 
(He et al 2002). It has also been reported that the propor-
tion of individuals with innately slow mEPHX activity was 
signiﬁ  cantly higher in patients with COPD (Koyama and 
Geddes 1998) and that a coding variant in codon 113 (exon 3) 
of mEPHX is associated with COPD and rapid FEV1 decline 
(Smith and Harrison 1997; Sandford et al 2001; Xaio et al 
2004). Thus, defective antioxidant defense mechanisms may 
in fact be responsible for the steeper decline of FEV1 in a 
number of COPD patients.
Hereditary emphysema due to reduced alpha -1- 
antitrypsin (A1AT) deﬁ  ciency (PiZZ homozygotes) is the 
primary example of a proven genetic factor predisposing to 
accelerated lung function decline in a particularly disparate 
phenotype (DeMeo and Silverman 2004). However, only 
a small number of cigarette-induced COPD patients may 
have under-diagnosed A1AT deﬁ  ciency as the main cause 
of their airﬂ  ow obstruction and other pathophysiological 
mechanisms appear to be more important (Molﬁ  no 2004). 
For example, COPD sufferers with a rapid decline in mean 
FEV1 (>150 ml/year) exhibited an association with the PiMZ 
genotype of the A1AT gene only when a family history of 
COPD was present (Yamada et al 2000). This suggests that 
additional factors to the A1AT genotype may contribute 
to the fast decline of lung function (Sandford et al 2001). 
Moreover, patients with A1AT deﬁ  ciency have been shown 
to have an increased frequency of the GSTP1 105Val poly-
morphism which impairs its antioxidant enzymatic activity 
(Rodriguez et al 2005). Other factors that may provoke en-
zymatic degradation of the extracellular matrix, leading to 
emphysema and airﬂ  ow limitation, include polymorphisms of 
the matrix metalloproteinases (MMPs) 1 and 12 genes which 
have been reported in association with rapid rate of decline 
of lung function in COPD (Joos et al 2002). 
At the 11th year of follow-up, the Lung Health study 
results show that airway hyperresponsiveness to metacholine, 
but not the FEV1 response to the ß2-agonist isoproterenol 
predicts the rate of decline of FEV1 in COPD (Anthonisen 
et al 2005). This seems to be the long-term clinical conﬁ  rma-
tion of a previous report (Joos et al 2003) in the same patient 
population that ß2-adrenoceptor polymorphisms may not 
be associated to the rate of FEV1 decline. In such previous 
study (Joos et al 2003), however, there was a signiﬁ  cant 
(p = 0.0007) negative association between heterozygosity at 
position Gln27 of the ß2-adrenoceptor and rapid decline in 
lung function suggesting that heterozygosity at position 27 
may be protective against an accelerated rate of decline in 
lung function in Caucasians. 
Taken together, the above results suggest that gene variants 
which incline the balance towards enhanced enzymatic degra-
dation of the lung parenchyma and towards increased airway 
hyperresponsiveness appear to contribute to the accelerated 
lung function decline in COPD (Yamada et al 2000; DeMeo 
and Silverman 2004; Molﬁ  no 2004; Xiao et al 2004).
Since exacerbations play such an important role in 
FEV1 decline (Donaldson et al 2002), it may be important 
to ﬁ  nd out if there is a genetic predisposition to AECOPD. 
In this regard, it has recently been reported that a SNP in 
the inﬂ  ammatory chemokine CCL1 gene encoding for a 
leukocyte chemoattractant is associated with an increased 
incidence of AECOPD in patients of Japanese origin (Taka-
batake et al 2006). Finally, genome-wide RNA interference 
screening to identify host factors required for infections is 
now possible and it is hoped that this technique would allow 
the identiﬁ  cation of other genetic factors associated with 
AECOPD (Agaisse et al 2005).
In summary, complete smoking cessation continues to be 
the best nonpharmacological approach to deter the rentless 
decline of lung function in COPD and, polymorphisms in an-
tioxidant, A1AT, and MMPs genes, seem associated with fast 
FEV1 decline. There may be gene–gene and gene–environ-
ment interactions that favor steeper lung function declines, 
but data are just emerging.
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